. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Pharmacotherapy. 2013 Apr 18;33(11):1199–1213. doi: 10.1002/phar.1270

Table 7.

2012 ACCP Dabigatran and Rivaroxaban Anticoagulation Reversal Summary⁹

	Dabigatran	Rivaroxaban
How to routinely monitor	No current validated method	No current validated Method
How to treat overanticoagulation	Hold dabigatran^a
	Supportive measures^b	Hold rivaroxaban^a
	Adequate diuresis	Supportive measures^b
	Consider hemodialysis	Consider oral activated charcoal
	Consider oral activated charcoal	Consider reversal agents (PCCs, rFVIIa)
	Consider reversal agents (PCCs, rFVIIa)

PCCs = prothrombin complex concentrates; rFVIIa = recombinant factor VIIa.

Holding the medication is often the only intervention required in most nonbleeding instances.

Supportive measures include fluid and blood product replacement. This should be considered if bleeding is suspected.